Space Industry and Business News  
Treat HIV Babies Early

"Children with HIV infection frequently show rapid disease progression within the first year of life due to their developing immune systems and susceptibility to other serious infections," said Elias Zerhouni, director of the U.S. National Institutes of Health. The NIH, though the National Institute of Allergy and Infectious Diseases, sponsored the trial.
by Ed Susman
UPI Correspondent
Sydney (UPI) July 25, 2007
Doctors said Wednesday that babies infected at birth with the virus that causes AIDS should be treated with antiretrovirals as soon as the infection is determined -- even within the first three weeks of life. Researchers stopped prematurely a study that attempted to determine if deferring treatment until signs of disease caused by HIV occurred might be better for the infants by preserving treatment options until they were older.

But 20 of the 125 children in the deferred arm died compared with 10 of 252 children in the immediate treatment group after 32 weeks of the study, forcing the trial oversight committee to terminate the project.

"Starting antiretroviral therapy early in children who are born with HIV infection reduces mortality by 75 percent," said Amy Violari, director of clinical pediatric trials in Soweto, South Africa, in a late-breaker oral presentation at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Sydney. "These results support the need for enhanced prophylactic mother-to-child-transmission programs, early infant diagnosis and effective transition to care."

In the study that could change worldwide treatment guidelines, doctors said that by starting treatment early, 96 percent of infants survived the first year of life, but for children for whom treatment was deferred until they showed signs of illness, the one-year survival was 84 percent.

In the Children with HIV Early Antiretroviral Therapy trial, doctors recruited 377 children for a three-arm trial. One group of 125 children would not receive treatment until they suffered signs of disease. In the other two study arms, 252 children in the CHER trial were begun on antiretroviral therapy immediately. Most of the children were treated with nevirapine monotherapy. One group was scheduled to have treatment interrupted after the first birthday; the second group would be treated until the second birthday, and then drugs would be withdrawn until they become symptomatic. The children will be followed for a minimum of 3.5 years.

"Children with HIV infection frequently show rapid disease progression within the first year of life due to their developing immune systems and susceptibility to other serious infections," said Elias Zerhouni, director of the U.S. National Institutes of Health. The NIH, though the National Institute of Allergy and Infectious Diseases, sponsored the trial.

In the United States, guidelines suggest treating infants at the time that they are diagnosed with HIV infection.

Even though the trial doctors suggest treating children as soon as possible, the realities of medical treatment in resource-limited areas -- the rural and impoverished areas of the world where HIV/AIDS is prevalent -- may preclude implementation of that advice.

"This is very important data," said Annette Sohn, an assistant professor of pediatric infectious diseases at the University of California-San Francisco who is working on pediatric HIV research in Ho Chi Minh City, Vietnam.

"It shows that by withholding treatment from these infants it may be too late to reduce mortality," she told United Press International.

However, Sohn said that in resource-limited settings, identification of children with HIV often cannot be accomplished until the child actually shows signs of disease due to lack of health infrastructure. "We are dealing with multiple layers of limitation," she said. "The most important limitations are the lack of healthcare personnel; the inability of women in these areas to receive ante-natal care, and the lack of laboratory capacity to perform some of these tests."

Sohn also noted that because treatment options are also limited in these areas, the early treatment that gets children to the first or second birthdays may result in creating a resistant virus that will give these children no treatment options as they age.

She said the CHER trial goal to interrupt treatment after a year or two when the child's immune system may be heartier is an attempt to preserve those drugs until later in life. HIV infection, which leads to AIDS without treatment, is presently incurable, although access to a wide variety of drugs in wealthier nations makes long-term effective treatment possible.

Sohn told UPI the study may change guidelines on treating infants, but each area of the world will develop its own guidelines based on available resources.

Source: United Press International

Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola



Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News


Revealing The Global Threat Of Bird Flu
Geelong, Australia (SPX) Jul 24, 2007
The Lecture, Avian Influenza Epizooties: Where do we stand in 2007, was presented by Dr Bernard Vallat, Director General of the Paris-based World Organisation for Animal Health (OIE). According to Dr Vallat the current epidemic of highly pathogenic avian influenza is a major global concern. One of the main constraints to controlling the outbreaks is the weakness of national veterinary services in many developing countries.







  • Vizada Launches SkyFile Access For Better Mobile Satellite Data Transfer
  • Bringing Mobile Cellular Phones To The Skyways
  • Rockwell Collins And ARINC Sign Agreement For Broadband Offering
  • Academic Group Releases Plan To Share Power Over Internet Root Zone Keys

  • Spaceway 3 Is Delivered To The Spaceport For Its Mid-August Ariane 5 Launch
  • Russian Space Firm Signs 14 Deals For Commercial Rocket Launches
  • Sea Launch To Resume Zenit Launches In October
  • Russia Proton-M Booster Puts US Satellite Into Orbit

  • Steering Aircraft Clear Of Choppy Air
  • EAA AirVenture 2007
  • Sensors May Monitor Aircraft For Defects Continuously
  • Goodrich Contributes Technology For Environmentally-Friendly Engine Research Program

  • LockMart And Northrop Grumman TSAT Team Announces Partnership With Juniper Networks
  • Northrop Grumman Wins Production Contract For E-2D Advanced Hawkeye
  • Raytheon To Develop Next Generation DIB Architecture
  • ViaSat Wins Order In MIDS Tactical Network Terminal Lot 8 Award

  • UCF And Holochip Announce Global Licensing Agreement For Zoom Lens Patents
  • Nature's Secrets Yield New Adhesive Material
  • Smart Fabric Biosensors Will Monitor Respiration Rate And Body Temperature In Real Time
  • BAE Systems To Produce Field Programmable Gate Array For Space Use

  • New SIDC Commander Has The Wright Stuff
  • NASA Administrator Names Ryschkewitsch As New Chief Engineer
  • Hall Appoints Feeney To Top GOP Position On Space And Aeronautics Subcommittee
  • Dodgen Joins Northrop Grumman As Vice President Of Strategy For Missile Systems Business

  • DigitalGlobe Expands Commercial Imagery Distribution Network In Australia And New Zealand
  • DMCii Wins ESA Satellite Imaging Contract
  • Campaign Prepares For Future Land-Surface Monitoring
  • Envisat Captures Breath Of Volcano

  • First Lockheed Martin-Built GPS Satellite Marks 10 Years In Service
  • Nokia Makes Finding Yourself Faster With New A-GPS Service
  • Poplar Creek Installs ProLink ProStar GPS To Enhance Golfer Experience And Deliver Advertising Revenues
  • SANYO Easy Street Portable Navigation Systems Make Their Debut

  • The content herein, unless otherwise known to be public domain, are Copyright Space.TV Corporation. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space.TV Corp on any Web page published or hosted by Space.TV Corp. Privacy Statement